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to be expected. We therefore measured the plasma levels of
tPA in the perfusion solution and systemic levels before,
during, and after the perfusion in seven patients undergoing
RHFP.
METHODS
All patients undergoing RHFP were informed explic-
itly about the procedure and gave written consent. The
technique of RHFP has been described previously.6,7,13
After surgical thrombectomy was completed, the common
femoral artery and vein of the affected limb were cannu-
lated, and the catheters were connected to a heart-lung
machine that contained a bubble oxygenator (Bentley-5;
Baxter, Irvine, Calif) (Fig 1). The heart-lung machine was
prefilled with 700 mL of gelatine solution (Haemaccel;
Behringwerke AG, Marburg/Lahn, Germany) to which
5000 IU of heparin and 20 mval of bicarbonate were
added. A rubber tourniquet was wrapped tightly around
the groin just above the cannulation site to prevent the
entry of the perfusion solution into the systemic circula-
tion through the soft tissue of the leg. A Steinmann pin
was introduced into the superior iliac crest and served as
an anchor to prevent the tourniquet from sliding distally
and obstructing the cannulation catheters. The extremity
was wrapped in an aluminum blanket to create heat isola-
tion, and the extracorporeal circuit was initiated. Steady-
state hemodynamic conditions within the circuit were
established, and the perfusion solution was warmed to
40°C, which took 20 to 30 minutes of perfusion depend-
ing on the volume and the initial temperature of the per-
fused extremity. After that, 0.5 mg/kg of body weight of
tPA diluted in 50 mL of 0.9% saline solution was infused
through the arterial line of the heart-lung machine over a
period of 30 minutes. Simultaneously, 500,000 kallikrein
Fibrinolytic therapy is a well-established form of treat-
ment for a variety of diseases, including deep venous
thrombosis (DVT). However, because of the possible
bleeding complications,1-4 fibrinolysis can only be per-
formed in a select group of patients.
With all contraindications taken into account, throm-
bolytic therapy is feasible in only about 15% of patients with
DVT.5 The restricted use of systemic fibrinolysis has led to
the development of alternative techniques; one of them is
the regional hyperthermic fibrinolytic perfusion (RHFP)
model.6,7 Regional perfusion with an extracorporeal circuit
was first described by Creech et al in 19588 and has been
mainly used in the treatment of advanced melanoma.9 With
isolated fibrinolytic perfusion, residual thrombi after surgi-
cal thrombectomy can be addressed intraoperatively with
high concentrations of the thrombolytic agent, while at the
same time minimizing its systemic levels. Additionally, the
temperature in the perfused area can be kept at a higher
level; in vitro studies have shown this higher temperature to
increase the fibrinolytic activity of tissue plasminogen acti-
vator (tPA).10,11 The fibrinolytic agent used in the RHFP
model, tPA, is removed from the circulation by the liver and
has a short half-life of 3 to 5 minutes.12 Under the condi-
tions of an isolated extracorporeal perfusion with lack of the
liver passage, impacts on the pharmacokinetics of tPA had
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Purpose: The aim of this study was to investigate the pharmacokinetics of tissue plasminogen activator (tPA) under the
conditions of an isolated extracorporeal circuit.
Methods: Plasma levels of tPA were measured in the perfusion solution and in central venous blood before, during, and
after the perfusion in seven patients undergoing regional hyperthermic fibrinolytic perfusion with tPA in addition to
surgical thrombectomy for extended deep venous thrombosis. 
Results: After 15 minutes of fibrinolytic perfusion, the level of tPA in the perfusion solution was 10,427 ± 4432
ng/mL, and after 30 minutes the maximum level of 19,726 ± 5630 ng/mL was reached. After 60 minutes when the
perfusion was discontinued, tPA concentrations dropped to 15,931 ± 4818 ng/mL. In central venous blood, tPA lev-
els increased to a maximum of 230.7 ± 89.6 ng/mL after 60 minutes of perfusion, which represented 1.4% of the con-
centration measured in the perfusion solution at the same time. With disconnection of the extracorporeal circuit, the
tPA levels in central venous blood decreased rapidly and reached a level of 24.1 ± 8.7 ng/mL after 120 minutes.
Conclusion: The use of regional hyperthermic fibrinolytic perfusion in the treatment of extended deep venous throm-
bosis makes it possible to achieve extremely high concentrations of tPA in the perfusion solution. At the same time, the
entry of the fibrinolytic agent into the systemic circulation is minimized. (J Vasc Surg 2001;33:165-9.)
inactivation units of aprotinin was infused into the sys-
temic circulation by means of a peripheral venous line.
After the infusion of the fibrinolytic agent was completed,
the isolated extracorporeal perfusion of the extremity with
the tPA-containing solution was kept up for 60 minutes.
After completion of the fibrinolytic perfusion, the perfu-
sion solution was directed into a cell-saver, and the leg was
perfused with 1000 to 1500 mL of gelatine solution to
wash out any remaining intravascular tPA. Afterwards, the
leg was filled up with blood that was donated earlier by the
patient and the washed cell-saver blood. The venous and
arterial catheters as well as the Steinmann pin were
removed, and the cannulation sites were closed.
Plasma levels of tPA were measured in the perfusion
solution of the heart-lung machine and in central venous
blood. The samples from the perfusion solution were
obtained from a three-way stopcock placed in the venous
line of the heart-lung machine directly before the oxygena-
tor. After the sample was obtained, the line was flushed with
10 mL of sodium chloride, 0.9%. The samples from the sys-
temic circulation were obtained from a central venous line.
Five milliliters of blood was drawn before obtaining the
sample to avoid dilution effects, and the line was also
flushed afterwards with 10 mL of 0.9% saline solution.
One sample was taken from the extracorporeal circuit
immediately before adding the fibrinolytic agent, and one
sample was obtained from the central venous line simulta-
neously (time 0). Further simultaneous sampling was done
15, 30, 45, and 60 minutes after perfusion start time.
Additionally, central venous samples were obtained after
disconnection of the extracorporeal circuit and restoration
of distal perfusion (time x) as well as after 120 minutes.
The samples were collected in 5-mL EDTA vials
(Monovette, Sarstedt, Germany), which were cooled in ice
and immediately taken to the laboratory. Ten microliters of
PPACK solution (5 mg D-phenylalanyl-2-propyl-L-argi-
nine-methylchloride-ketone diluted in 9.538 mL of 0.1
mmol/L hydrogen chloride solution; pH 4.0) per milliliter
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Fig 1. Diagram of heart-lung machine and cannulation sites in groin.
Table I. Plasma levels of tPA in the perfusion solution of the extracorporeal circuit before and during the fibrinolytic
perfusion
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Total 
Time (min) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL)*
0† 3.2 1.7 189.1 1 104.1 136.2 41.9 68.1 ± 75.7
15 10,250 8,656 17,020 2,741 9,005 13,020 12,280 10,427 ± 4432
30 22,620 15,520 24,970 10,940 16,470 26,610 20,920 19,726 ± 5630
45 20,940 13,920 19,850 11,240 22,720 17,970 21,430 18,302 ± 4239
60 19,370 12,850 18,850 7,909 20,220 12,480 19,780 15,931 ± 4818
*Total tPA levels were calculated as the mean value ± SD. 
†Time 0 represents the time point immediately before tPA was administered to the perfusion solution.
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of blood was added. The samples were cooled for 15 addi-
tional minutes and then centrifuged. The plasma was pipet-
ted in separate glass tubes and frozen at –20°C. Without an
interruption of the cooling process, the samples were taken
to a specialized laboratory where tPA concentrations were
measured with an immunologic assay (enzyme-linked
immunosorbent assay) according to the method described
by Seifried et al.14 A two-site microplate enzyme-linked
immunosorbent assay with a polyclonal/monoclonal anti-
body configuration was developed. The plasma samples
containing tPA were diluted 1:10 or more in phosphate-
buffered saline–bovine serum albumin (PBS-BSA) and
incubated (100 µL per well) in the polyclonal antibody-
coated microtiter plates for 2 hours at room temperature.
After four washes with PBS containing 0.5 g/L Tween 20,
100 µL per well of monoclonal anti-tPA–antibody conju-
gated to horseradish peroxidase (Boehringer Mannheim,
Mannheim, Germany) diluted to 0.006 units peroxidase
activity per milliliter in PBS-BSA was incubated for 1 hour.
After three further washes with PBS-Tween, solid phase
horseradish peroxidase–activity was quantified with incuba-
tion for 30 minutes with 100 µL o-phenylene diamine sub-
strate solution followed by 100 µL 2.25 mol/L sulfuric
acid and measurement of optical density (A492 nm) with a
microplate reader (Dynatech MR 600; Dynatech,
Denkendorf, Germany).
The total tPA levels were described as mean value ±
SD. The statistical analyses were performed with the
Student t test.
RESULTS
Plasma levels of tPA were measured in seven patients.
In four (57%) patients, tPA concentrations in the perfu-
sion solution were elevated, ranging between 41.9 and
189.1 ng/mL even before addition of the fibrinolytic
agent. The mean tPA level in the perfusion solution before
starting fibrinolysis was 68.1 ± 75.7 ng/mL (Table 1); the
respective level in the systemic circulation was 4.9 ± 1.8
(Table II) and thereby significantly lower (P < .001).
During the 30 minutes when tPA was constantly
added to the perfusion solution, a nearly linear increase in
the plasma levels of tPA in the perfusion solution was pre-
sent. After the infusion of tPA was finished, a decrease in
tPA plasma levels in the perfusion solution was noted
(Table I). The maximum tPA level of 19,726 ± 5630
ng/mL was reached after 30 minutes, and at the end of
the perfusion after 60 minutes the mean tPA level in the
perfusion solution was 15,931 ± 4818 ng/mL (Table I).
In all seven patients, plasma levels of tPA in the systemic
circulation increased during the fibrinolytic perfusion (Table
II). The highest plasma level of tPA in the systemic circula-
tion was reached after 60 minutes at the end of the perfusion
with 230.7 ± 89.6 ng/mL, showing a continuous increase in
systemic tPA levels during the fibrinolytic perfusion. The
entry of fibrinolytic agents into the systemic circulation dur-
ing perfusion is also shown by the relation of systemic tPA
levels and tPA levels in the perfusion solution (Fig 2): after
15 minutes of perfusion, the mean systemic tPA level was at
0.7% of the perfusion solution level, after 30 minutes it
increased to 0.8%, after 45 minutes it increased to 1.2%, and
after 60 minutes at the end of the perfusion it reached 1.4%
(Fig 2). At the time of disconnection of the extracorporeal
circuit and restoration of perfusion to the limb (time x), the
mean tPA level in central venous blood had decreased to
207.7 ± 95.7 ng/mL, and after 120 minutes it had dropped
significantly to 24.1 ± 8.7 ng/mL (Table II).
DISCUSSION
Using the RHFP model and infusing 0.5 mg tPA per
kilogram of body weight, we could achieve extremely high
levels of the thrombolytic agent in the perfusion solution.
The concentrations measured in the perfusion circuit were
70 to 100 times higher than the levels of tPA of 200 to
300 ng/mL described in the literature that were achieved
with systemic fibrinolysis for DVT.15 With a mean peak
level of almost 20,000 ng/mL, the tPA concentrations
measured in the RHFP model were also significantly
higher than the levels described in systemic fibrinolysis
with pulmonary embolism and myocardial infarction.16,17
In the treatment of pulmonary embolism, Tebbe et al16
measured a peak level of 3200 ± 840 ng/mL after bolus
injection of 50 mg tPA. That was followed by an infusion
of 50 mg tPA over 2 hours, resulting in a mean plasma
level of 520 ng/mL. Tanswell et al,17 describing fibrino-
lysis in acute myocardial infarction, applied a bolus of 15
mg tPA followed by an infusion of 50 mg tPA over 30
Table II. Plasma levels of tPA in the systemic blood before, during, and after the fibrinolytic perfusion
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Total
Time (min) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL)*
0† 5.4 4.9 2.5 8.1 3.3 5.5 4.8 4.9 ± 1.8
15 7.8 205.6 107.5 86.6 7.5 50.3 34.9 71.5 ± 70.0
30 30.9 293.2 85.8 302.1 115.7 193.4 117.3 162.6 ± 104.0
45 119.9 308.3 219 181.1 103.8 341.5 254.1 218.2 ± 90.1
60 151.4 395.2 193.1 296.5 185.9 147.9 245.9 230.7 ± 89.6
x‡ 274.5 216.4 339.9 199.8 87.9 80.1 255.5 207.7 ± 95.7
120 33.3 26.4 24.5 9 32.4 16.2 27 24.1 ± 8.7
*Total tPA levels were calculated as the mean value ± SD. 
†Time 0 is the point immediately before administration of tPA to the perfusion solution.
‡Time x is the time at which the perfusion catheters were removed and blood flow to the limb was restored.
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minutes. They measured a peak level of 3200 ± 840
ng/mL. In a study with healthy volunteers, Seifried et al14
applied systemically 0.5 mg tPA per kilogram of body
weight, the same dose we used in the RHFP model, and
achieved peak plasma levels of about 2000 ng/mL.
In recent years local, catheter-directed thrombolysis
has replaced the systemic therapy in many instances. With
the catheter-directed technique, the thrombolytic agent is
administered directly into the thrombus, thereby decreas-
ing the total dose required for therapy and the systemic
drug concentration.18 Although there are numerous stud-
ies in which the clinical results of catheter-directed throm-
bolysis are addressed,18 there are few data regarding the
pharmacokinetics and the local and systemic levels of tPA
reached with this technique. Rauber et al19 described sys-
temic tPA levels of 60.3 ± 4.3 ng/mL after catheter-
directed application of 20 mg of tPA in patients with
peripheral arterial occlusive disease. Higher dosages of up
to 100 mg of tPA have been used in local thrombolysis,20
with no information being provided about what tPA levels
were achieved. To our knowledge, there is no study in
which the pharmacokinetics and systemic and local levels
of tPA in systemic versus catheter-directed thrombolysis
are compared.
The peak plasma levels of about 20,000 ng/mL,
which were reached with the RHFP model, are, to our
knowledge, the highest levels achieved in the clinical appli-
cation of tPA. The high plasma levels are a result of the
high initial dose of tPA and of the altered pharmocokinet-
ics in the isolated circuit. Because the distribution volume
for tPA is smaller and the elimination of tPA in the liver is
avoided in isolated perfusion, the tPA levels had still
remained at 80% of the peak level at the end of the perfu-
sion. This is in contrast to systemic fibrinolysis, where tPA
has only a short half-life and is eliminated from the circu-
lation rapidly.14
Even though the use of an isolated, extracorporeal cir-
cuit diminishes the entry of tPA into the systemic circula-
tion, it cannot avoid it totally. During the perfusion, the
tPA levels in the systemic circulation increased constantly
and reached 230 ng/mL after 60 minutes (Table II). After
15 minutes of perfusion, the systemic tPA concentration
was at 0.7% of the concentration measured in the perfusion
solution; after 60 minutes it had approached 1.4% (Fig 2).
At the time of disconnection of the extracorporeal circuit
the systemic levels had decreased to 207.7 ng/mL, and
after 120 minutes the concentration had dropped signifi-
cantly to 24.1 ng/mL (Table II). Accordingly, systemic
levels of tPA of 200 to 230 ng/mL were maintained for
about 30 to 45 minutes. Although these levels are lower
than the concentrations used in systemic thrombolysis,
they are 40 to 50 times higher than the baseline tPA levels
measured in the patients (Table II). Because a strong dose-
effect relationship has been demonstrated for tPA,21 this
could potentially lead to systemic bleeding complications
despite the use of the isolated extracorporeal circuit. On
the other hand, it has been shown that the application of
lower concentrations of tPA over a relatively short period
Fig 2. Relation between levels of tPA in central venous blood and in perfusion solution. Relative concentration of tPA in systemic blood
was calculated as tPA levels in central venous blood divided by respective tPA levels in perfusion solution times 100. It increased during
perfusion and after 60 minutes reached 1.4% of concentration in perfusion solution. tPA, Tissue plasminogen activator.
of time is probably of little clinical significance, especially if
high concentrations of plasmin inhibitors are present.22,23
The antiplasmin pool of the patients’ blood can be artifi-
cially elevated with the infusion of aprotinin, which inhibits
plasmin and thereby effectively counteracts the effects of
tPA.24-26 Clinically, aprotinin has been shown to reduce
blood loss in patients undergoing cardiopulmonary bypass
grafting.27 The combination of relatively low systemic tPA
levels (200-230 ng/mL) with a short application time of
30 to 45 minutes in addition to artificially elevated
antiplasmin levels in the patients’ blood should decrease
the risk of unwanted systemic effects of tPA.
In conclusion, extremely high concentrations of tPA
can be achieved in the perfusion solution with the use of
RHFP; at the same time the systemic levels of the throm-
bolytic agent can be minimized. The clinical results of this
method must be evaluated before any conclusions can be
drawn regarding its possible role as a supplement to surgi-
cal thrombectomy in the treatment of extended DVT.
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